We report a patient with progressive multifocal leukoencephalopathy (PML) after autologous stem cell transplantation (SCT) for non-Hodgkin's lymphoma (NHL). This is an unusual association, and to date only seven cases have been reported. This is the first case of PML after SCT treated with cidofovir, and the fifth case treated with this drug in a patient without human immunodeficiency virus (HIV) infection. In the previous four patients treated with cidofovir the outcome was discouraging, as was the case in this patient.
Progressive multifocal leukoencephalopathy is a neurological demyelinating disorder caused by JC polyomavirus, first reported in 1958 in a patient with chronic lymphocytic leukemia. 1 JC virus is ubiquitous, and the seroprevalence is up to 60% in young adults and up to 80% in elderly people. 2 Primary infection usually occurs during childhood and is often asymptomatic. 2 During primary infection the virus is transported to the kidney where it persists indefinitely. Disorders associated with severe cellular immunodeficiency such as hematological malignancies, solid tumors, connective tissue diseases, transplant patients, treatment with immunosuppressive agents, and especially HIV infection, can cause reactivation of the virus and PML. In immunocompromised patients the differential diagnoses of PML should be made with other central nervous system infections (as for example tuberculosis, fungi, nocardia, CMV) and noninfectious diseases such as lymphoma. So far, PML has been reported in seven cases after SCT. [3] [4] [5] [6] [7] [8] [9] Here, we report a case after autologous transplant for nonHodgkin's lymphoma treated with cidofovir. This case is the first case of PML after SCT treated with this antiviral agent. Cidofovir, with activity in vitro against Papoviridae, has been given to patients with HIV infection with controversial results. The experience in HIV-negative patients is limited to four cases, [10] [11] [12] [13] all of whom had a poor outcome.
Case report
A 60-year-old man diagnosed with mantle cell lymphoma received an autologous SCT in first complete remission (CR) after three different regimens of chemotherapy. The conditioning regimen consisted of cyclophosphamide (4800 mg/24 h ϫ 2 days) and fractionated total body irradiation (total dose 12 Gy), followed by infusion of CD34-selected peripheral blood stem cells (5 ϫ 10 6 CD34 cells/kg). Five months after SCT he developed a clinical and radiological picture that was diagnosed as bronchiolitis obliterans. Due to this complication the patient began treatment with prednisone (1 mg/kg/day) with a good response, although long-term oxygen therapy was needed. The prednisone dose was progressively decreased, but 5 months later (in the 10th month after SCT) he again needed high doses due to bronchiolitis reactivation.
Eleven months after SCT the patient developed a progressive weakness in his right arm and leg, dysphasia and apraxia. A cerebral MRI scan showed a focal area of white matter abnormality involving the left precentral area, without enhancement on post-gadolinium T1 weighted images, suggestive of PML ( Figure 1 ). Cerebrospinal fluid (CSF) examination disclosed normal values for glucose, protein and white cells, without evidence of malignancy. Microbiological analysis for bacteria, mycobacterium, fungi, enterovirus, herpes virus, and JC virus (by PCR) were all negative. Histological examination of sterotactic biopsies from the white matter lesion showed multiple foci of demyelination ( Figure 2 ) with large hyperchromatic oligodendrocytes, some with ground glass nuclei and a central zone, corresponding to viral inclusions ( Figure 3 ). This histology is typical of PML. The JC virus genome was demonstrated by PCR 14 in the brain tissue. At the time of PML diagnosis, the lymphoma remained in complete remission, and the CD4 + lymphocyte count was 535/mm 3 . As there were pre- liminary data showing that cidofovir could improve the course in some patients affected with PML, the patient received a total of six doses of cidofovir (each of 5 mg/kg; two initial doses with a 1-week interval between doses and four subsequent doses at 2 weekly intervals, each preceded by probenecid and i.v. saline). Therapy was tolerated without complications, but in spite of the treatment the patient experienced rapid and progressive neurologic deterioration, with complete aphasia, right hemiplegia and dysphagia. An MRI performed after five doses of cidofovir showed clear progression of the lesions (Figure 4 ). The patient died 5 months after the start of the neurological symptoms. 
Discussion
Progressive multifocal leukoencephalopathy after SCT is an unusual complication, with only seven cases reported to date. [3] [4] [5] [6] [7] [8] [9] The main characteristics of these cases are summarized in Table 1 . Five patients received autologous transplants, and two allogeneic SCTs from matched unrelated donors. The underlying diseases were three chronic myeloid leukemias, three NHL, and one acute myeloid leukemia. As with our case, the majority of these patients (all except one) were conditioned with cyclophosphamide and total body irradiation. The bone marrow was only manipulated in one case (purged by mafosfamide). The median time of commencing the neurological symptoms after the Ara-C (i.t.) mafosfamide NHL = non-Hodgkin's lymphoma; AML = acute myeloid leukemia; CML = chronic myeloid leukemia; CY-TBI = cyclophosphamide and total body irradiation; i.v. = intravenous; i.t. = intrathecal; IFN = interferon; PBSC = peripheral blood stem cells. transplant was 10.5 months (1-17 months), similar to our patient (9 months). The CD4 count was only available in four patients and ranged from 149 to 348/mm 3 , figures lower than the CD4 count in our case (535/mm 3 ). These data suggest that although the CD4 count is an important predisposing factor, as in HIV patients, other factors may be implicated in PML after BMT. This is also supported by the fact that even in the transplant patients with the lowest CD4 counts, these were not as low as in HIV patients with PML. [15] [16] [17] Most patients with HIV infection and PML have CD4 counts less than 100/mm 3 . Another interesting aspect of our case is the treatment with cidofovir. This antiviral agent, with in vitro activity against Papovaviridae, has been used in patients with HIV and PML with some favorable outcomes. 15, [17] [18] [19] However, the improvement observed in HIV patients may be due to the effect of concomitant highly active antiretroviral therapy (HAART). To assess this possibility some studies have compared the treatment of PML patients with HAART alone and HAART plus cidofovir. A higher rate of JC virus DNA neutralization in the CSF, and a better outcome has been found in some, 15, 17 but not all cidofovir studies. 16 Cidofovir is generally well tolerated, and the most common reported adverse effects are nephrotoxicity (manifested usually as proteinuria), vomiting, neutropenia and ocular hypotony. 20 
Bone Marrow Transplantation
Four HIV-negative patients with PML treated with cidofovir have been reported. [10] [11] [12] [13] The underlying diagnoses were: idiopathic CD4 lymphocytopenia, chronic lymphocytic leukemia, dermatomyositis and systemic lupus erythematosus. The outcome was fatal in all of these patients, a few months after the diagnosis has been made. Although, in one of the patients, disappearance of the JC virus genome from the cerebrospinal fluid and stabilization of the MRI picture were noted initially, the patient finally died. 10 Ours is the first transplant patient treated with this drug and the evolution was no better than in previously reported cases. This short experience with cidofovir in HIV-negative patients is thus discouraging.
Of the seven patients with PML after BMT only two had prolonged survival times (more than 1 year, and one is probably cured). Both of them received treatment with interleukin-2. 7, 8 It is also interesting that both showed an increase in CD4 counts from 149/mm 3 to 364/mm 3 , and from 340/mm 3 to 540/mm 3 . It is difficult to determine if this positive outcome was related to the treatment or to the partial reconstitution of the immune system which could have been spontaneous or due to the treatment itself.
In summary, cidofovir was of no clinical value in our case of PML after SCT, as in other HIV-negative cases reported in the literature. Other therapies should be investigated in this unusual clinical context.
